Helomics® Corporation and Ariel Precision Medicine, Inc. sign a services agreement to Advance Clinical Genomics in Precision Medicine Applications

<< Back
Dec 20, 2017

Helomics® Corporation and Ariel Precision Medicine, Inc. sign a services agreement to Advance Clinical Genomics in Precision Medicine Applications

PITTSBURGH, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and Ariel Precision Medicine, Inc. (Ariel), an integrated genomics and digital health company enabling early treatment and targeted management of complex chronic diseases, today announced that they have signed a service agreement to support the further commercial application of Ariel’s proprietary, clinically integrated genomic assay, PancreasDx®.

Furthermore, this agreement solidifies the shared vision of making the Pittsburgh region a leader in Precision Medicine, as Helomics and ARIEL explore opportunities to work together in research and clinical applications, to establish a Next-Generation Sequencing (NGS)” hub” and provide products and services to life-sciences organizations within the region and beyond.

The terms and conditions established between Ariel and Helomics were not disclosed.

Gerald J. Vardzel Jr., President and CEO of Helomics said, “We are excited to finalize a services agreement with Ariel to serve as the clinical laboratory for their genomics assay, PancreasDx. The agreement is further evidence of our commitment to commercial clinical grade NGS here in Pittsburgh and our partnership with ARIEL, a precision medicine leader.”

Jessica Gibson, President and CEO of ARIEL stated, “Helomics and Ariel share a Precision Medicine vision for Pittsburgh and, by leveraging Helomics’ sophisticated CLIA laboratory and clinical grade NGS platform, we will be able to further accelerate the commercialization of our genomics panels for early detection and long-term management of chronic diseases such as pancreatitis. We look forward to expanding our scientific and commercial activities with Helomics as we work to leverage Pittsburgh’s rich technology, professional expertise and cutting-edge science to advance life sciences and healthcare technology in the region.

About Helomics Corporation

Helomics® is a precision diagnostic company and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace.  In addition to its proprietary precision diagnostics for oncology, Helomics offers boutique CRO services that leverage our patient-derived tumor models, coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to our client’s specific needs. Helomics has signed a joint venture term sheet with Skyline Medical Inc. (NASDAQ:SKLN), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, to leverage the Helomics D-CHIP™ platform to develop and market new approaches for personalized cancer diagnosis and care.

Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. 

For more information, please visit: www.Helomics.com.

About Ariel Precision Medicine, Inc.

Ariel is an integrated genomics and digital health company delivering precision medicine solutions enabling the early diagnosis, prognosis and management of complex chronic diseases. Ariel’s technologies can lead a paradigm shift from targeting single gene (Mendelian) genetics to using multifaceted, complicated gene to gene interactions that interface with familial and environmental factors to provide a more comprehensive view of disease trajectory and precise therapeutic options. Results from next generation sequencing of more than 1500 genetic targets are integrated with a patient’s symptoms and complex medical information using systems modeling, machine learning and other advanced reporting technology to create decision support tools. The process compares a patient and his or her disease behavior against databases of well-mapped, complex disease patterns to help determine both the underlying cause of the disease and the optimal treatment plan.  Ariel’s headquarters are in Pittsburgh, PA, with additional offices in Chicago and Los Angeles.  

For more information, please visit:  www.arielmedicine.com

Contacts:

Helomics
Gerald J. Vardzel Jr., Chief Executive Officer
(412) 432-1500
gvardzel@helomics.com

Investors
KCSA Strategic Communications
Elizabeth Barker
(212) 896-1203
skln@kcsa.com

Primary Logo

Source: Skyline Medical Inc.